Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Muller-Wieland, D; Merkel, M; Verket, M; Marz, W; von Eckardstein, A.
Pathophysiological principles of dyslipoproteinaemia
DEUT MED WOCHENSCHR. 2021; Doi: 10.1055/a-1516-2441
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

März Winfried

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Die effektive Reduktion atherogener Lipoproteine hat dazu beigetragen, dass die Rate an Arteriosklerose-bedingten kardiovaskularen Komplikationen in den letzten 50 Jahren in etwa halbiert wurde. Dennoch werden in den nachsten Jahren kardiovaskulare Erkrankungen weltweit die haufigste Todesursache sein. Der Fokus dieser ubersicht liegt daher auf der klinischen Bedeutung der Pathophysiologie von Veranderungen im Lipid- und Lipoproteinstoffwechsel. Abstract The effective reduction of atherogenic lipoproteins has contributed to the rate of atherosclerosis-related cardiovascular complications being approximately halved over the last 50 years. Nevertheless, cardiovascular disease will be the leading cause of death worldwide in the coming years. The focus of this review is on the clinical significance of the pathophysiology of changes in lipid and lipoprotein metabolism. Elevated levels of atherogenic lipoproteins are a causal risk factor for atherosclerotic cardiovascular disease. Primary forms of hypercholesterolaemia have a significantly higher ASCVD risk because of the already lifelong LDL elevation (higher cumulative LDL exposure for the vessel wall). Secondary changes in lipid and lipoprotein metabolism (e.g. in diabetes or hypothyroidism) must be excluded or treated. Regulatory key steps in the pathophysiology of lipid metabolism and atherosclerotic plaque are "drug targets" for existing and new lipid and lipoprotein modifying therapies.

Find related publications in this database (Keywords)

atherogenic lipoproteins

ASCVD risk

regulatory key steps

diabetes mellitus

© Med Uni Graz • Imprint